Moreover, the combination of the FABP5‐targeting nanocarrier co‐delivery system with RFA and PD‐L1 monoclonal antibodies demonstrated exceptional efficacy as a therapeutic strategy against HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.